Skip to main content
. 2023 Aug 19;14(2):400–417. doi: 10.1007/s13346-023-01407-7

Fig. 1.

Fig. 1

Experimental design and treatment schedule for the assessment of antiparkinsonian effects of the different prepared intranasal TAN-NLC formulations versus TAN suspension